Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands

Zynga

Here's how a boutique online game developer, a coronavirus vaccine developer, and the largest cannabis company in the world can all add wealth to your portfolio.

3 Extraordinary Growth Stocks to Buy Now

Pfizer

Should You Be Concerned About COVID Vaccine Efficacy Against the South African Variant?

Johnson & Johnson

It's simply not an apples-to-apples comparison.

Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Canada purchases additional 4 million doses of Moderna's COVID-19 Vaccine

Canada Purchases Additional 4 Million Doses of Moderna's COVID-19 Vaccine

BioNTech SE

CureVac B.V

Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session.  US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), the two companies that have received  emergency use authorization for vaccine candidates in the U.S., confirmed supply deals with the federal government.

COVID-19 Vaccine Updates: US Strikes 100M-Dose Supply Deals With Moderna, Pfizer, EU Starts Rolling Review Of CureVac Vaccine

How Long Until We Reach Herd Immunity? Expert Timelines Vary

Moderna Inc. said late Thursday the U.S. government has bought an additional 100 million doses of the company's COVID-19 vaccine, bringing its confirmed order commitment to 300 million doses. Moderna already has supplied 41 million doses to date, and more than 22 million U.S. residents have received the vaccine, the second to be approved in the U.S. Moderna remains on track to deliver the first 100 million doses in the first quarter of 2021 and the second order of 100 million doses would be delivered in the second quarter of 2021.

Moderna says U.S. bought 100 million more doses of COVID-19 vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. government purchases additional 100 million doses of Moderna's COVID-19 Vaccine.

U.S. Government Purchases Additional 100 Million Doses of Moderna's COVID-19 Vaccine

Abbott Labs

Gritstone Oncology Inc

RedHill Biopharma

Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.

4 Top COVID Stocks to Buy in February

GlaxoSmithKline

Eli Lilly

Sorrento Therapeutics Inc

Vir Biotechnology

These biotech companies may be among the winners of the coronavirus treatment race -- if all goes well in clinical trials.

How Risky Are These Heavily Shorted COVID Stocks?

BioNTech and Moderna were first to market with a COVID-19 vaccine based on messenger-RNA technology and it has had a transformative on both companies and their share prices. Formerly focused on R&D, both companies are now likely to earn $5 - $15bn per annum over a five-year period.

BioNTech: Undervalued Based On COVID-19 Vaccine Revenue, But Moderna Is The Better Long-Term Bet

Shares of Moderna Inc. were up 0.1% in trading on Wednesday, the day after the company said it plans to supply 5 million doses of its COVID-19 vaccine to Taiwan and another 10 million doses to Colombia, starting in mid-2021. Neither country has authorized the vaccine.

Moderna to supply 10 million doses to Colombia, 5 million doses to Taiwan

Moderna stock has rallied by over 75% since the beginning of 2021 and currently trades at levels of around $185 per share. So what's driving these gains?

Why Has Moderna Stock Already Rallied 75% In 2021?

Is Moderna Stock Overvalued?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces COVID-19 vaccine supply agreements with the Government of Taiwan and the Government of Colombia.

Moderna Announces COVID-19 Vaccine Supply Agreements with the Government of Taiwan for 5 Million Doses and the Government of Colombia for 10 Million Doses

Does Moderna (MRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Moderna (MRNA) is a Great Choice

AvroBio Inc

Moderna (NASDAQ: MRNA) shares are trading higher amid South Africa stopping distribution of the AstraZeneca COVID-19 vaccine due to ineffectiveness in treating a disease variant. Moderna is working on a competing vaccine.

Why Moderna, Avrobio, And More Are Moving Today

Moderna is unlikely to follow in GameStop's footsteps.

Moderna Short Interest Is Rising. Here's Why I'm Not Worried.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.

Moderna to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 25, 2021

Novavax

Both have a plan to tackle emerging coronavirus variants.

Here's Why These 2 Vaccine Makers Are Most Likely to Beat New COVID Strains

Should Investors Worry About New Coronavirus Variants?

Anavex Life Sciences

Axsome Therapeutics

Hologic

Cassava Sciences Inc

Meridian Bioscience

Vaxart

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Biotech Bonanza: COVID Launches Science at Warp Speed

The biotech announced two positive developments.

Why Moderna Stock Bounced Back Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use

Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use

Moderna Inc. said Wednesday that it has increased its commitment to provide its COVID-19 vaccine to Switzerland by 80%, to 13.5 million doses. The drug maker had initially committed in August 2020 to provide 4.5 million doses of its COVID-19 vaccine candidate to Switzerland, and that was increased to 7.5 million doses in December.

News for Moderna Stock (MRNA)